Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 26:16:25-34.
doi: 10.2147/CEOR.S439725. eCollection 2024.

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review

Santi Aprilianti #  1 , Auliasari M Utami  1 , Auliya A Suwantika #  1   2   3 , Neily Zakiyah #  1   2 , Vanji Ikhsan Azis  4
Affiliations
Review

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review

Santi Aprilianti et al. Clinicoecon Outcomes Res. .

Abstract

The World Health Organization (WHO) recommends dolutegravir (DTG), a human immunodeficiency virus (HIV) medicine, as the first- and second-line treatment for all populations because, when compared to an efavirenz (EFV) regimen, plus two nucleoside reverse transcriptase inhibitors (NRTIs) has demonstrated significant effectiveness in HIV suppression in persons. This study aims to review evidence of the cost-effectiveness of DTG in combination with tenofovir and lamivudine compared with the standard of care for HIV therapy. The systematic review involved searching electronic databases for articles published between January 2018 and May 2022. Electronic database sources include PubMed, ScienceDirect, and EBSCO for articles on DTG in combination with tenofovir and lamivudine as subjects with cost-effectiveness outcomes. The inclusion criteria in this systematic review were studies about the cost-effectiveness analysis (CEA) of DTG in combination with tenofovir and lamivudine, written in English. A total of 145 articles were identified from three databases. After removing nine duplicates, 142 articles were screened by title and abstract, excluding 123 articles. After a full-text screening of 19 articles, five articles were selected for further analysis. Five articles reviewed in sub-Saharan Africa, India, and China implemented different modelling methods for CEA but produced similar results. The results of these studies demonstrate that it is more cost-effective than standard care for HIV treatment. The study conducted in sub-Saharan Africa from 2018 to 2020 showed a cost-effective result with disability-adjusted life years averted (DALY averted) by 83%; in India, it resulted in incremental cost-effectiveness ratio (ICER) $130 per year of live-saved (YLS); and a study in China found that dolutegravir plus tenofovir and lamivudine led to 0.006 incremental quality-adjusted life years (QALYs) with cost savings of $64. The DTG regimen is cost-effective and recommended for HIV therapy in all studies that provide results.

Keywords: antiretroviral therapy; cost-effectiveness; dolutegravir; efavirenz; human immunodeficiency virus.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Article selection flow process.
See this image and copyright information in PMC

References

    1. Mbhele N, Chimukangara B, Gordon MHIV-1. Integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents. 2021;57(5):106343. doi: 10.1016/j.ijantimicag.2021.106343 - DOI - PubMed
    1. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. HIV treatment-interim guidance; 2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18....Accessed January 23, 2024.
    1. World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations; 2023. Available from: https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-.... Accessed January 23, 2024.
    1. World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service, delivery and monitoring: recommendations for a public health approach; 2021. Available from: https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-.... Accessed January 23, 2024. - PubMed
    1. Zhao Y, Keene C, Griesel R, et al. AntiRetroviral therapy in second-line: investigating tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial. Wellcome Open Res. 2021;6:1–13. doi: 10.12688/WELLCOMEOPENRES.16597.1 - DOI - PMC - PubMed